NovoCure/$NVCR
14:30
21:55
05:15
12:40
20:00
1D1W1MYTD1Y5YMAX
About NovoCure
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
Ticker
$NVCR
Sector
Primary listing
Employees
1,488
Headquarters
Baar, Switzerland
Website
NovoCure Metrics
BasicAdvanced
$1.4B
-
-$1.61
0.75
-
Price and volume
Market cap
$1.4B
Beta
0.75
52-week high
$34.13
52-week low
$10.87
Average daily volume
1.6M
Financial strength
Current ratio
1.546
Quick ratio
1.493
Long term debt to equity
69.528
Total debt to equity
233.772
Interest coverage (TTM)
-12.71%
Profitability
EBITDA (TTM)
-161.587
Gross margin (TTM)
75.53%
Net profit margin (TTM)
-27.66%
Operating margin (TTM)
-27.05%
Effective tax rate (TTM)
-18.04%
Revenue per employee (TTM)
$430,000
Management effectiveness
Return on assets (TTM)
-8.41%
Return on equity (TTM)
-50.60%
Valuation
Price to revenue (TTM)
2.204
Price to book
4.2
Price to tangible book (TTM)
4.2
Price to free cash flow (TTM)
-21.723
Free cash flow yield (TTM)
-4.60%
Free cash flow per share (TTM)
-0.59
Growth
Revenue change (TTM)
11.17%
Earnings per share change (TTM)
15.35%
3-year revenue growth (CAGR)
5.78%
10-year revenue growth (CAGR)
38.63%
3-year earnings per share growth (CAGR)
27.12%
10-year earnings per share growth (CAGR)
-14.82%
What the Analysts think about NovoCure
Analyst ratings (Buy, Hold, Sell) for NovoCure stock.
Bulls say / Bears say
GAAP revenue in Q2 2025 rose 6% year-over-year to $158.8 million, surpassing analyst consensus by $4.6 million, reflecting solid commercial execution across glioblastoma and new indications.
Novocure submitted a premarket approval (PMA) application to the FDA for TTFields therapy in locally advanced pancreatic cancer, backed by Phase 3 PANOVA-3 results showing a statistically significant and clinically meaningful survival benefit, which could unlock a substantial new revenue stream.
Active patients on TTFields therapy reached 4,331 as of June 30, 2025—a 9.3% increase year-over-year—highlighting accelerating adoption across different indications.
Gross margin shrank to 73% in Q3 2025 from 77% a year ago, due to higher costs from launching the new Head Flexible Electrode arrays, pre-reimbursement expenses for NSCLC patients, and increased tariffs, resulting in tighter profitability.
The company posted a net loss of $37.3 million (–$0.33 EPS) for Q3 2025, deeper than the $30.6 million loss a year earlier, highlighting continued investment spending that delays reaching profitability.
There remains significant regulatory risk: the FDA’s decision on the premarket approval application for pancreatic cancer isn’t expected until the second half of 2026, postponing any potential new revenue from this indication.
Data summarised monthly by Lightyear AI. Last updated on 3 Nov 2025.
NovoCure Financial Performance
Revenues and expenses
NovoCure Earnings Performance
Company profitability
NovoCure News
AllArticlesVideos
Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress
Business Wire3 weeks ago
Novocure to Report Third Quarter 2025 Financial Results
Business Wire1 month ago
Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting
Business Wire1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for NovoCure stock?
NovoCure (NVCR) has a market cap of $1.4B as of November 03, 2025.
What is the P/E ratio for NovoCure stock?
The price to earnings (P/E) ratio for NovoCure (NVCR) stock is 0 as of November 03, 2025.
Does NovoCure stock pay dividends?
No, NovoCure (NVCR) stock does not pay dividends to its shareholders as of November 03, 2025.
When is the next NovoCure dividend payment date?
NovoCure (NVCR) stock does not pay dividends to its shareholders.
What is the beta indicator for NovoCure?
NovoCure (NVCR) has a beta rating of 0.75. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.